Standard treatment for hepatitis B is either based on interferon or on nucleos(t)ide analogues. Available evidence on treatment outcome by hepatitis B virus genotype was summarized and analysed to determine whether the genotype has a substantial role in selecting treatment.
Methods
Abstracts from PubMed, the European Association for the Study of the Liver and the American Association for the Study of the Liver Diseases were screened for publications with at least 30 patients and reporting hepatitis B treatment results (hepatitis B e antigen [HBeAg] seroconversion, loss of HBeAg or loss of HBV DNA) broken down by hepatitis B genotypes. Twenty reports were identified and included. Forest-plot techniques were applied to visualize the association of HBV genotypes (A versus D and B versus C) with treatment outcome given by type of treatment and HBeAg status. The potential size of a treatment by genotype interaction was estimated.
Results
Treatment response to nucleos(t)ide analogues is not significantly influenced by HBV genotype in HBeAg-positive or HBeAg-negative individuals. In contrast, HBV genotypes are informative concerning responses to interferon treatment in all patients with genotype A versus D and in HBeAg-positive patients with genotype B versus C.
Conclusion
If no contraindications are present, interferon may be considered as first-line therapy in all genotype A patients and in individuals with genotype B who are HBeAg positive. However, confirmation of this observation in a prospective clinical trial is warranted, because this analysis is explorative and hypothesis generating only.
References
1.
de FranchisR., HadengueA., LauG.EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version).J Hepatol2003; 39Suppl 1: S3–S25.
2.
LiawY.F., LeungN., GuanR., LauG.K., MericanI.Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.J Gastroenterol Hepatol2003; 18: 239–245.
3.
MannsM.P., WedemeyerH., MeyerS.Diagnostik, verlauf und therapie der hepatitis-B-virusinfektion -ergebnisse einer evidenzbasierten konsensuskonferenz der deutschen gesellschaft für verdauungs- und stoffwechselkrankheiten in zusammenarbeit mit dem kompetenznetz hepatitisn [Diagnosis, progression and therapy of hepatitis-B-virus infection – results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and in cooperation with the Hepatitis Competence Network].Z Gastroenterol2004; 42: 677–678.
4.
LokA.S., McMahonB.J.Chronic hepatitis B: update of recommendations.Hepatology2004; 39: 857–861.
5.
ChangT.T., GishR.G., de ManR.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med2006; 354: 1001–1010.
6.
LaiC.L., ShouvalD., LokA.S.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med2006; 354: 1011–1020.
7.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med2005; 352: 2682–2695.
8.
ErhardtA., BlondinD., HauckK.Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.Gut2005; 54: 1009–1013.
9.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet2005; 365: 123–129.
10.
FlinkH.J., van ZonneveldM., HansenB.E., de ManR.A., SchalmS.W., JanssenH.L.Treatment with Peg-Interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.Am J Gastroenterol2006; 101: 297–303.
11.
ThakurV., GuptanR.C., KazimS.N., MalhotraV., SarinS.K.Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent.J Gastroenterol Hepatol2002; 17: 165–170.
12.
WestlandC.E., YangH., DelaneyW.E.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology2003; 38: 96–103.
13.
LindhM., AnderssonA.S., GusdalA.Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus–large-scale analysis using a new genotyping method.J Infect Dis1997; 175: 1285–1293.
14.
ChuC.J., KeeffeE.B., HanS.H.Hepatitis B virus genotypes in the United States: results of a nationwide study.Gastroenterology2003; 125: 444–451.
15.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
16.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
17.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
18.
DeeksJ., AltmanD., BradburnM.Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic Reviews in Health Care. Meta-Analysis in Context. Edited by EggerM., SmithG., & AltmanD.. London: BMJ Publishing Group2001; pp. 285–312.
19.
ZollnerB., PetersenJ., SchaferP.Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment.Clin Infect Dis2002; 34: 1273–1277.
20.
LurieY., MannsM.P., GishR.G.The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B.J Hepatol2005; 42Suppl 2: 184.
21.
ChanH.L., WongM.L., HuiA.Y.Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.World J Gastroenterol2003; 9: 2695–2697.
22.
KaoJ.H., LiuC.J., ChenD.S.Hepatitis B viral genotypes and lamivudine resistance.J Hepatol2002; 36: 303–304.
23.
YuenM.F., TanakaY., LaiC.L.Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.Intervirology2003; 46: 373–376.
24.
ChienR.N., YehC.T., TsaiS.L., ChuC.M., LiawY.F.Determinants for sustained HBeAg response to lamivudine therapy.Hepatology2003; 38: 1267–1273.
25.
SuzukiF., TsubotaA., AraseY.Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.Intervirology2003; 46: 182–189.
26.
BoninoF., MarcellinP., LauG.K.Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.Gut2007; 56: 699–705.
27.
WestlandC., DelaneyW., YangH.Hepatitis B virus genotypes and virological response in 694 patients in phase III studies of adefovir dipivoxil1.Gastroenterology2003; 125: 107–116.
ChanH.L., HuiA.Y., WongV.W., ChimA.M., WongM.L., SungJ.J.Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.Hepatology2005; 41: 1357–1364.
30.
KaoJ.H., WuN.H., ChenP.J., LaiM.Y., ChenD.S.Hepatitis B genotypes and the response to interferon therapy.J Hepatol2000; 33: 998–1002.
31.
WaiC.T., ChuC.J., HussainM., LokA.S.HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.Hepatology2002; 36: 1425–1430.
32.
ChuR.H., MaL.X., WangG., ShaoL.H.Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B.World J Gastroenterol2005; 11: 4753–4757.
33.
ZhaoH., KurbanovF., WanM.B.Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.Clin Infect Dis2007; 44: 541–548.
34.
LiuC.J., LaiM.Y., ChaoY.C.Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.Hepatology2006; 43: 742–749.
35.
ZhangX., ZoulimF., HabersetzerF., XiongS., TrepoC.Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B.J Med Virol1996; 48: 8–16.
36.
HadziyannisS., LauG.K., MarcellinP.Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon α-2a (40 kDa) (PEGASYS®).J Hepatol2005; 42Suppl 2: 177.
37.
CornbergM., ProtzerU., DollingerM.M.Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.Z Gastroenterol2007; 45: 1281–1328.
38.
LinC.L., KaoJ.H.To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B.Clin Infect Dis2007; 44: 1665–1666.
39.
CooksleyW.G., PiratvisuthT., LeeS.D.Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat2003; 10: 298–305.
